Docetaxel for the treatment of hormone-refractory metastatic prostate cancer

  • Technology appraisal guidance
  • TA101
  • Published: 
Download guidance (PDF)

1 Guidance

1.1 Docetaxel is recommended, within its licensed indications, as a treatment option for men with hormone-refractory metastatic prostate cancer only if their Karnofsky performance-status score is 60% or more.

1.2 It is recommended that treatment with docetaxel should be stopped:

  • at the completion of planned treatment of up to 10 cycles, or

  • if severe adverse events occur, or

  • in the presence of progression of disease as evidenced by clinical or laboratory criteria, or by imaging studies.

1.3 Repeat cycles of treatment with docetaxel are not recommended if the disease recurs after completion of the planned course of chemotherapy.